Brandon Kitay, MD
Psychiatry · New Haven, CTNPI 1235549353
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $50,982 of the $58,569 with a category attached, or 87.0%. 8 manufacturers reported payments, led by Boehringer Ingelheim at 46.5% of the total. Reporting peaked in 2024 at $16,612 and has fallen 67.0% since, to $5,484 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $1009.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$27K
- Biogen$12K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- Boehringer Ingelheim International GmbH$5K
- Sage Therapeutics, LLC$3K
- Johnson & Johnson$3K
- plus $3K from 2 others
What the payments were for
- Consulting fees$50,98287%
- Speaking & faculty fees$500%
- Travel & lodging$6,38111%
- Food & beverage$1,1572%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 42 | $27,257 |
| Biogen | 2 | $12,064 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $5,060 |
| Boehringer Ingelheim International GmbH | 5 | $4,834 |
| Sage Therapeutics, LLC | 1 | $3,120 |
| Johnson & Johnson | 2 | $3,087 |
| Merck | 1 | $3,023 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,569 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 12 | $653 |
| Quetiapine Fumarate | 15 | $351 |
| Gabapentin | 13 | $132 |
| Clonazepam | 21 | $85 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New Haven
- Vladimir CoricNew Haven$133.7M
- Robert BermanNew Haven$126K
- Gerard SanacoraNew Haven$94K
- Christopher VandyckNew Haven$70K
- Paula ZimbreanNew Haven$61K
- Sarah FinebergNew Haven$34K
- Samuel WilkinsonNew Haven$30K
- Christopher PittengerNew Haven$19K
- Dan OrenNew Haven$17K
- Youngsun ChoNew Haven$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.